Indianapolis-based Simon Property Group Inc. said funds from operations rose 20 percent in the second quarter as rents and occupancies increased. The company raised its forecast for the year.
Wall Street's Perella Weinberg Partners LP took over at the beginning of July.
Pfizer Inc., the world’s biggest drugmaker, said it isn’t interested in breaking up its animal health unit after Indianapolis-based Eli Lilly and Co. expressed interest in buying some of its products.
Borders Group Inc.’s proposed liquidation will increase available U.S. retail space by about 6.3 million square feet as the industry struggles with near-record vacancy rates and stagnant rents.
Express Scripts Inc. agreed to buy Medco Health Solutions Inc. for $29.1 billion to become the largest pharmacy-benefits manager in the United States. Both have central Indiana operations.
Eli Lilly and Co. said patients with Alzheimer’s disease whose conditions worsened upon taking the experimental drug semagacestat didn’t improve after dosing was halted.
Not-for-profits that compete with insurers such as WellPoint Inc. are eligible for $3.8 billion in U.S. financing under the health law, and the government expects more than a third of the loans not to be repaid.
Dapagliflozin would be the first in a new class of diabetes treatments called SGLT2-inhibitors that work by letting patients excrete excess blood sugar in their urine. Indianapolis-based Eli Lilly and Co. is among several companies pursuing similar drugs.
Eli Lilly & Co. CEO John C. Lechleiter said Germany’s overhaul of drug pricing lacked transparency and the new policy creates “uncertainty” for the company’s business planning.
Now five years old, the Indiana Toll Road deal has yet to turn a profit, or break even, for its two overseas investors. The $3.8 billion contract, however, has been a bargain for the taxpayers of Indiana.
The High Court in London on Tuesday denied Lilly’s request for a judgment without trial against Neopharma Ltd., the closely held company that has European marketing rights for the generic version of the drug known chemically as olanzapine.
Eli Lilly and Co., the Indianapolis-based drugmaker whose best-selling schizophrenia medicine Zyprexa survived a patent challenge in Britain two years ago, has asked a United Kingdom judge to reject a parallel lawsuit by a generic drug company.
Lilly has 33 drugs in the second and third stages of clinical trials, including medicines for cancer, diabetes and Alzheimer’s disease, up from seven in 2005, the Indianapolis-based company said Thursday.
The Connecticut-based company on Monday agreed to buy Sweden’s Niscayah Group AB for $1.2 billion—its biggest deal since Stanley Works’ $4.4 billion purchase of Black & Decker Corp.
The U.S. Supreme Court has refused to revive a bid to press a $6.8 billion class-action suit against Eli Lilly and Co. over the marketing of Zyprexa, the company’s schizophrenia treatment.
Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said an analysis of a 148-patient trial found no evidence that their experimental Bydureon diabetes drug causes prolonged heart rhythms.
Eli Lilly and Co. and Boehringer Ingelheim GmbH’s Trajenta medicine for Type 2 diabetes has been recommended for approval in Europe, putting the drug on track to enter the region’s market this year.
The U.S. government needs to open its borders to attract and retain talented scientists for drugmakers to employ, Eli Lilly & Co. CEO John Lechleiter plans to tell a technology conference Thursday.
Former Senator Evan Bayh and former White House Chief of Staff Andrew Card will tour the U.S. in a campaign by the Chamber of Commerce urging small businesses to fight regulations they say are stunting job growth.
Republic’s agreement to add the Airbus planes, which have a value of about $7 billion at list prices, comes as it pursues a $120 million restructuring plan for Frontier after buying the Denver-based airline out of bankruptcy in 2009.
